Factors associated with adherence to nucleos(t)ide analogs in chronic hepatitis B patients: results from a 1-year follow-up study

Figures & data

Table 1 Characteristics of the study patients (N=211)

Characteristics
Age, years	29.6±7.8
Male	167 (79)
Positive for HBeAg	137 (65)
CHB medication
Telbivudine	63 (30)
Lamivudine	27 (13)
Entecavir	20 (9)
Adefovir	101 (48)
History of NUC treatment
Yes	68 (32)
No	143 (68)
History of drug resistance
No	180 (85)
Yes	31 (15)

Note: Data are presented as mean ± standard deviation or number (percentage).

Abbreviations: CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; NUC, nucleos(t)ide analog.

Figure 1 Mean adherence rates across the four time periods of the four different NUC medications.

Abbreviation: NUC, nucleos(t)ide analog.

Table 2 Estimates from GEE models of indicators of adherence to NUC for CHB patients

	Beta	SE	P-value
Age	0.01	0.02	0.75
Sex
Male	–	–
Female	0.96	0.25	<0.001
HBeAg status
Negative	–	–
Positive	0.30	0.27	0.27
CHB medication
Telbivudine	–	–
Lamivudine	−1.21	0.54	0.02
Entecavir	−1.05	0.43	0.01
Adefovir	−0.29	0.28	0.31
History of NUC treatment
Yes	–	–
No	1.19	0.35	<0.01
History of drug resistance
No	–	–
Yes	2.07	0.36	<0.001

Abbreviations: CHB, chronic hepatitis B; GEE, generalized estimating equation; HBeAg, hepatitis B e antigen; NUC, nucleos(t)ide analog; SE, standard error.